Cover Image
市場調查報告書

血管損傷的開發中產品分析

Vascular Injury - Pipeline Review, H1 2014

出版商 Global Markets Direct 商品編碼 200499
出版日期 內容資訊 英文 44 Pages
訂單完成後即時交付
價格
Back to Top
血管損傷的開發中產品分析 Vascular Injury - Pipeline Review, H1 2014
出版日期: 2014年05月15日 內容資訊: 英文 44 Pages
簡介

所謂血管損傷是指血管的內皮層(內部表面)的損傷。有血管損傷的人,在動脈和靜脈有裂傷和挫傷、穿刺、粉碎等情況。由於動脈比起靜脈血壓高,如果動脈有損傷會比靜脈流失更多的血液。再加上動脈週邊比靜脈有更多的神經集聚著,動脈損傷比靜脈損傷更易成為重症。血管損傷的主要症狀為紫斑、腫脹、疼痛、出血、損傷部附近的發麻和脆弱性等。主要治療方法包含麻醉的疼痛治療,及非類固醇抗發炎治療,抗生素等。

本報告提供全球各國的血管損傷治療用開發中產品的開發情形相關分析、開發中產品的最新趨勢,及臨床實驗的各階段產品一覽,再加上主要企業簡介、主要藥物概要、最新的產業趨勢等調查,並將結果概述為以下內容。

目錄

簡介

  • 分析範圍

血管損傷概要

治療藥的開發

  • 血管損傷之開發中產品:概要
  • 血管損傷之開發中產品:比較分析

各企業開發中的血管損傷治療藥

在大學/研究機關研究中的血管損傷治療藥

開發中產品的概要

  • 臨床實驗階段的產品
  • 初期階段的產品

血管損傷治療藥:開發中產品一覽(各企業)

血管損傷治療藥:各研究中的產品一覽(大學/研究機關)

血管損傷治療藥的開發企業

  • Advanced Cell Technology, Inc.
  • Shire Plc
  • Polyphor Ltd.
  • ChemoCentryx, Inc.

血管損傷:治療藥的評估

  • 單劑治療藥的情況
  • 各標的
  • 各行動機制
  • 各投藥法
  • 各分子類型

藥物簡介

  • SHP-613
    • 產品概要
    • 功能機制
    • 研究開發(R&D)的發展情形
  • Hemangioblast Program
  • CCX-872
  • POL-5551
  • 血管損傷之幹細胞治療

血管損傷治療藥:最新的藥物簡介

血管損傷治療藥:開發暫停的產品

血管損傷相關產品的開發里程碑

  • 值得注意的最新趨勢、新聞稿(共7件)

附錄

圖表一覽

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC5013IDB

Global Markets Direct's, 'Vascular Injury - Pipeline Review, H1 2014', provides an overview of the Vascular Injury's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Vascular Injury, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Vascular Injury and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Vascular Injury
  • The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in the therapeutics development for Vascular Injury and enlists all their major and minor projects
  • The report summarizes all the dormant and discontinued pipeline projects
  • A review of the Vascular Injury products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • A detailed assessment of monotherapy and combination therapy pipeline projects
  • Coverage of the Vascular Injury pipeline on the basis of target, MoA, route of administration and molecule type
  • Latest news and deals relating related to pipeline products

Reasons to buy

  • Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Identify and understand important and diverse types of therapeutics under development for Vascular Injury
  • Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
  • Devise corrective measures for pipeline projects by understanding Vascular Injury pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Vascular Injury Overview
  • Therapeutics Development
    • Pipeline Products for Vascular Injury - Overview
    • Pipeline Products for Vascular Injury - Comparative Analysis
  • Vascular Injury - Therapeutics under Development by Companies
  • Vascular Injury - Therapeutics under Investigation by Universities/Institutes
  • Vascular Injury - Pipeline Products Glance
    • Clinical Stage Products
    • Early Stage Products
  • Vascular Injury - Products under Development by Companies
  • Vascular Injury - Products under Investigation by Universities/Institutes
  • Vascular Injury - Companies Involved in Therapeutics Development
    • Advanced Cell Technology, Inc.
    • Shire Plc
    • Polyphor Ltd.
    • ChemoCentryx, Inc.
  • Vascular Injury - Therapeutics Assessment
    • Assessment by Monotherapy Products
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Drug Profiles
    • SHP-613 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Hemangioblast Program - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • CCX-872 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • POL-5551 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Stem Cell Therapy for Vascular Injury - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • Vascular Injury - Recent Pipeline Updates
  • Vascular Injury - Dormant Projects
  • Vascular Injury - Product Development Milestones
    • Featured News & Press Releases
      • Nov 08, 2013: Proteo, Inc. / Proteo Biotech AG: Patient Recruitment and Treatment in Elafin CABG Phase II Clinical Trial Completed
      • Nov 16, 2012: Bio3 Research Receives Hong Kong Patent For HMGB1 Antibodies To Treat Vascular Diseases
      • Jan 10, 2012: Amorcyte Announces Expansion Of Intellectual Property Coverage For AMR-001
      • Mar 30, 2009: Amorcyte Reports Phase I Results Of AMR-001 To Improve Recovery From Severe Heart Attack At ACC Annual Scientific Session
      • Apr 01, 2008: Amorcyte Completes Phase I Trial Of Stem Cell Therapy For Acute Myocardial Infarction
      • May 08, 2007: Amorcyte Cardiac Cell Therapy Trial Completes Second Of Four Phases
      • Jun 05, 2006: Amorcyte, Inc Opens Cell Therapy Trial For Cardiovascular Disease At Emory University
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for Vascular Injury, H1 2014
  • Number of Products under Development for Vascular Injury - Comparative Analysis, H1 2014
  • Number of Products under Development by Companies, H1 2014
  • Number of Products under Investigation by Universities/Institutes, H1 2014
  • Comparative Analysis by Clinical Stage Development, H1 2014
  • Comparative Analysis by Early Stage Development, H1 2014
  • Products under Development by Companies, H1 2014
  • Products under Investigation by Universities/Institutes, H1 2014
  • Vascular Injury - Pipeline by Advanced Cell Technology, Inc., H1 2014
  • Vascular Injury - Pipeline by Shire Plc, H1 2014
  • Vascular Injury - Pipeline by Polyphor Ltd., H1 2014
  • Vascular Injury - Pipeline by ChemoCentryx, Inc., H1 2014
  • Assessment by Monotherapy Products, H1 2014
  • Number of Products by Stage and Target, H1 2014
  • Number of Products by Stage and Mechanism of Action, H1 2014
  • Number of Products by Stage and Route of Administration, H1 2014
  • Number of Products by Stage and Molecule Type, H1 2014
  • Vascular Injury Therapeutics - Recent Pipeline Updates, H1 2014
  • Vascular Injury - Dormant Projects, H1 2014

List of Figures

  • Number of Products under Development for Vascular Injury, H1 2014
  • Number of Products under Development for Vascular Injury - Comparative Analysis, H1 2014
  • Number of Products under Development by Companies, H1 2014
  • Comparative Analysis by Early Stage Products, H1 2014
  • Assessment by Monotherapy Products, H1 2014
  • Number of Products by Top 10 Target, H1 2014
  • Number of Products by Stage and Top 10 Target, H1 2014
  • Number of Products by Top 10 Mechanism of Action, H1 2014
  • Number of Products by Stage and Top 10 Mechanism of Action, H1 2014
  • Number of Products by Top 10 Route of Administration, H1 2014
  • Number of Products by Stage and Top 10 Route of Administration, H1 2014
  • Number of Products by Top 10 Molecule Type, H1 2014
  • Number of Products by Stage and Top 10 Molecule Type, H1 2014
Back to Top